Immunopathogenesis of inflammatory myopathies
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Immune-mediated mechanisms appear to play a primary role in the pathogenesis of polymyositis (PM) and dermatomyositis (DM). The serum of patients with active DM has high levels of circulating complement fragments C3b, C4b, and C5b-9 membranolytic attack complex (MAC) and demonstrates a very high C3 uptake in an vitro assay system. The MAC and the immune complex-specific C3bNEO fragment are deposited on the endomysial capillaries early in the disease and lead sequentially to loss of capillaries, muscle ischemia, muscle fiber necrosis, and perifascicular atrophy. In contrast, in PM the muscle fiber injury is initiated by sensitized CD8+ cytotoxic T cells that recognize heretofore unknown and probably endogenous muscle antigens in the context of major histocompatibility complex (MHC) class I expression. A restricted (oligoclonal) pattern of T-cell receptor with prominence of Va1, Vb6, and Vb15 genes is noted within the endomysial infiltrates suggesting that the T-cell response is antigen driven. In both PM and DM, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 are upregulated in the endomysial endothelial cells and function as ligands for the leukocyte integrins leukocyte function-associated antigen (LFA)-1 and very late activating antigen (VLA)-4, allowing activated lymphocytes to adhere to the endothelial cells and migrate to the muscle fibers. Among viruses, only the retroviruses human immunodeficiency virus (HIV) and human T-cell lymphotropic virus (HTLV)-1 have been convincingly shown to trigger PM, which is mediated by nonviral-specific, cytotoxic CD8+ cells. The treatment of inflammatory myopathies remains empirical. Many patients respond to steroids to some degree and for some period of time. Azathioprine, methotrexate, cyclosporine, cyclophosphamide, and plasmapheresis can be of mild to moderate benefit. High-dose intravenous immunoglobulin (IVIg) is a promising therapeutic modality for some patients resistant to therapies. In a controlled study, IVIg was effective in DM not only in improving the clinical symptoms but also in reversing the underlying immunopathology. The role of IVIg in PM and IBM is under study in control trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polymyositis and Dermatomyositis: (First of Two Parts)
Bohan, A., & Peter, J. B. (1975) · New England Journal of Medicine · doi:10.1056/nejm197502132920706 · Cited by 5,059
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Self-citationPolymyositis, Dermatomyositis, and Inclusion-Body Myositis
Dalakas, M. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252107 · Cited by 938
Self-citationPolymyositis, Dermatomyositis, and Inclusion Body Myositis
Holton, J., Wedderburn, L. R., & Hanna, M. G. (2013) · UCL Discovery (University College London) · Cited by 764
INCLUSION BODY MYOSITIS: OBSERVATIONS IN 40 PATIENTS
LOTZ, B. P., ENGEL, A. G., NISHINO, H., STEVENS, J. C., & LITCHY, W. J. (1989) · Brain · doi:10.1093/brain/112.3.727 · Cited by 573
Microvascular Deposition of Complement Membrane Attack Complex in Dermatomyositis
Kissel, J. T., Mendell, J. R., & Rammohan, K. W. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602063140601 · Cited by 524
Microvascular changes in early and advanced dermatomyositis: A quantitative study
Emslie‐Smith, A. M., & Engel, A. G. (1990) · Annals of Neurology · doi:10.1002/ana.410270402 · Cited by 426
Basta, M., & Dalakas, M. C. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117520 · Cited by 396
Self-citationEmslie-Smith, A. M., Arahata, K., & Engel, A. G. (1989) · Human Pathology · doi:10.1016/0046-8177(89)90128-7 · Cited by 349
HTLV-1 AND POLYMYOSITIS IN JAMAICA
Morgan, O. S., Mora, C., Rodgers-Johnson, P., & Char, G. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91793-5 · Cited by 337
Expression of immunoreactive major histocompatibility complex products in human skeletal muscles
Karpati, G., Pouliot, Y., & Carpenter, S. (1988) · Annals of Neurology · doi:10.1002/ana.410230111 · Cited by 325
DERMATOMYOSITIS (SYSTEMIC ANGIOPATHY) OF CHILDHOOD
BANKER, B. Q., & VICTOR, M. (1966) · Medicine · doi:10.1097/00005792-196607000-00001 · Cited by 319
Engel, A. G., & Arahata, K. (1986) · Human Pathology · doi:10.1016/s0046-8177(86)80180-0 · Cited by 304
Polymyositis Associated With AIDS Retrovirus
Dalakas, M. C. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380170097026 · Cited by 260
Self-citationHohlfeld, R., & Engel, A. G. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90006-x · Cited by 254
Neuromuscular diseases associated with human immunodeficiency virus infection
Dalakas, M. C., & Pezeshkpour, G. H. (1988) · Annals of Neurology · doi:10.1002/ana.410230713 · Cited by 253
Self-citationMendell, J. R. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530240033013 · Cited by 207
Dermatomyositis of Childhood: Ultrastructural Alterations of Muscle and Intramuscular Blood Vessels
Banker, B. Q. (1975) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-197501000-00005 · Cited by 188
Psychiatric Reports: Whether and How
(1966) · The Lancet · doi:10.1016/s0140-6736(66)90494-6 · Cited by 185
Arahata, K., & Engel, A. G. (1986) · Annals of Neurology · doi:10.1002/ana.410190203 · Cited by 165
Askanas, V., Engel, W. K., & Alvarez, R. B. (1992) · PubMed Central · Cited by 159
Mantegazza, R., Andreetta, F., Bernasconi, P., Baggi, F., Oksenberg, J. R., Simoncini, O., Mora, M., Cornelio, F., & Steinman, L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116533 · Cited by 152
Polymyositis Mediated by T Lymphocytes That Express the γ/δ Receptor
Hohlfeld, R., Engel, A. G., Ii, K., & Harper, M. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103283241303 · Cited by 142
Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle
Leff, R. L., Love, L. A., Miller, F. W., Plötz, P. H., Greenberg, S. J., Klein, E., & Dalakas, M. C. (1992) · The Lancet · doi:10.1016/0140-6736(92)91134-t · Cited by 141
Self-citationTreatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin
Soueidan, S. A., & Dalakas, M. C. (1993) · Neurology · doi:10.1212/wnl.43.5.876 · Cited by 130
Self-citationHTLV-I Polymyositis in a Patient Also Infected with the Human Immunodeficiency Virus
Wiley, C. A., Nerenberg, M. I., Cros, D. P., & Soto-Aguilar, M. C. (1989) · New England Journal of Medicine · doi:10.1056/nejm198904133201507 · Cited by 120
Bailliere's Clinical Neurology
Harris, J. (1997) · Emergency Medicine Journal · doi:10.1136/emj.14.4.271-a · Cited by 115
Hohlfeld, R., & Engel, A. G. (1991) · Annals of Neurology · doi:10.1002/ana.410290509 · Cited by 108
Progressive Encephalopathy and Myopathy in Transgenic Mice Expressing Human Foamy Virus Genes
Bothe, K., Aguzzi, A., Lassmann, H., Rethwilm, A., & Horak, I. D. (1991) · Science · doi:10.1126/science.1650034 · Cited by 103
Morphometric analysis of skeletal muscle capillary ultrastructure in inflammatory myopathies
Jerusalem, F., Rakusa, M., Engel, A. G., & Macdonald, R. D. (1974) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(74)90157-9 · Cited by 97
Inclusion Body Myositis: New Concepts
Sekul, E. A., & Dalakas, M. C. (1993) · Seminars in Neurology · doi:10.1055/s-2008-1041132 · Cited by 89
Self-citationClinical, Immunopathologic, and Therapeutic Considerations of Inflammatory Myopathies
Dalakas, M. C. (1992) · Clinical Neuropharmacology · doi:10.1097/00002826-199210000-00001 · Cited by 75
Self-citationLeon‐Monzon, M., Illa, I., & Dalakas, M. C. (1994) · Annals of Neurology · doi:10.1002/ana.410360414 · Cited by 74
Self-citationSinoway, P. A., & Callen, J. P. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360305 · Cited by 73
β-amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis
Askanas, V., Engel, W. K., Alvarez, R., & Glenner, G. G. (1992) · The Lancet · doi:10.1016/0140-6736(92)90388-j · Cited by 60
Current treatment of the inflammatory myopathies
Dalakas, M. C. (1994) · Current Opinion in Rheumatology · doi:10.1097/00002281-199411000-00008 · Cited by 55
Self-citationLeon‐Monzon, M., & Dalakas, M. C. (1992) · Annals of Neurology · doi:10.1002/ana.410320215 · Cited by 52
Self-citationPathology of the inflammatory myopathies.
Karpati, G., & Carpenter, S. (1993) · PubMed · Cited by 49
Enteroviruses and Human Neuromuscular Diseases
Dalakas, M. C. (2014) · ASM Press eBooks · doi:10.1128/9781555818326.ch16 · Cited by 22
Self-citationDalakas, M. C. (1990) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30375-x · Cited by 21
Self-citationTreatment of Polymyositis and Dermatomyositis with Corticosteroids: A First Therapeutic Approach
Dalakas, M. C. (1988) · Elsevier eBooks · doi:10.1016/b978-0-409-95191-2.50016-1 · Cited by 17
Self-citationRetrovirus-related neuromuscular diseases
Dalakas, M. C., Illa, I., & de Monzón, M. (1994) · Springer eBooks · doi:10.1007/978-94-011-1422-6_10 · Cited by 2
Self-citation
Cited by
Polymyositis and dermatomyositis
Dalakas, M. C., & Hohlfeld, R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14368-1 · Cited by 1,416
Self-citationUpdate on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
ORANGE, J., HOSSNY, E., WEILER, C., BALLOW, M., BERGER, M., BONILLA, F., BUCKLEY, R., CHINEN, J., ELGAMAL, Y., & MAZER, B. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.015 · Cited by 653
How citation distortions create unfounded authority: analysis of a citation network
Greenberg, S. A. (2009) · BMJ · doi:10.1136/bmj.b2680 · Cited by 499
Ihim, S. A., Abubakar, S. D., Zian, Z., Sasaki, T., Saffarioun, M., Maleknia, S., & Azizi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.919973 · Cited by 378
Metadata
- Authors
- Dalakas, M. C.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1995-05
- Volume
- 37
- Issue
- S1
- Pages
- 74-86
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1997396678
- Cited by
- 163
- References
- 42
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.